Magnostics

Magnostics is developing a rapid screening test for Acute Mesenteric Ischemia, which has mortality rate of 60-80%

OWNER

Valentine Le Mauff (See Profile)


Sector

Biotech

Stage

Prototyping, preclinical

Country

Ireland

Unique solution: Specific and sensitive biomarker for AMI, patent pending

Projected sales: $112.5M in 2032 resulting in a $1.8B company (assuming 16x multiplier)

Market: > $1 122M market growing at 9-12% CAGR

Status

–

IP Type

Trade secret

Time

–

Countries

Coverage

A provisional patent application has been submitted with the USPTO and a PCT application will be submitted latter this year.

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Under evaluation at least till: 26th of March 2o23

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar